Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tovorafenib in MAPK pathway aberrant solid tumors
NCT04985604Phase 2Terminated
- Sponsor
- Day One Biopharmaceuticals
- Start
- Jul 2021
- Primary completion
- Jul 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 7
01
Overview
A Phase 2 trial of tovorafenib in melanoma, solid tumor, sponsored by Day One Biopharmaceuticals. Started Jul 2021; status: terminated.
02
Drugs
tovorafenib
03
Conditions
melanomasolid tumor
Beyond the preview
Go deeper on NCT04985604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04985604.